Synonyms: C188-9 [2] | TTI 101 | TTI101
Compound class:
Synthetic organic
Comment: TTI-101(formerly C188-9) is an orally bioavailable STAT3 transcription factor inhibitor. It blocks the tyrosine residue phosphorylation by Janus kinase (JAK) that mediates STAT3 activation, leading to downregulation of STAT3-mediated gene expression. This mechanism of action is considered as a valid approach for the treatment of inflammation, fibrosis, and a range of cancers [1,3].
|
|
No information available. |
Summary of Clinical Use |
TTI-101 was advanced as an oncology clinical lead. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | Phase 1 Interventional | Tvardi Therapeutics, Incorporated | ||
NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/Phase 2 Interventional | Tvardi Therapeutics, Incorporated | ||
NCT05384119 | Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor-Positive and Human Epithelial Receptor 2 (HER2)-Negative Breast Cancer | Phase 1/Phase 2 Interventional | Tvardi Therapeutics, Incorporated |